(1) This chapter does not: (a) require an insurer to cover the cost of: (i) administering an investigational drug under this chapter; or (ii) treating a patient with an investigational device under this chapter; or (b) prohibit an insurer from covering the cost of: (i) administering an investigational drug under this chapter; or (ii) treating a patient with an investigational device under this chapter.
(a) require an insurer to cover the cost of: (i) administering an investigational drug under this chapter; or (ii) treating a patient with an investigational device under this chapter; or
(i) administering an investigational drug under this chapter; or
(ii) treating a patient with an investigational device under this chapter; or
(b) prohibit an insurer from covering the cost of: (i) administering an investigational drug under this chapter; or (ii) treating a patient with an investigational device under this chapter.
(i) administering an investigational drug under this chapter; or
(ii) treating a patient with an investigational device under this chapter.
(2) Except as described in Subsection (3), an insurer may deny coverage to an eligible patient who is treated with an investigational drug or investigational device, for harm to the eligible patient caused by the investigational drug or investigational device.
(3) An insurer may not deny coverage to an eligible patient under Subsection (2) for: (a) the eligible patient's preexisting condition; (b) benefits that commenced before the day on which the eligible patient is treated with the investigational drug or investigational device; or (c) palliative or hospice care for an eligible patient that has been treated with an investigational drug or device, but is no longer receiving curative treatment with the investigational drug or device.
(a) the eligible patient's preexisting condition;
(b) benefits that commenced before the day on which the eligible patient is treated with the investigational drug or investigational device; or
(c) palliative or hospice care for an eligible patient that has been treated with an investigational drug or device, but is no longer receiving curative treatment with the investigational drug or device.
Copyright ©2024 LegalFix. All rights reserved. LegalFix is not a law firm, is not licensed to practice law, and does not provide legal advice, services, or representation. The information on this website is an overview of the legal plans you can purchase—or that may be provided by your employer as an employee benefit or by your credit union or other membership group as a membership benefit.
LegalFix provides its members with easy access to affordable legal services through a network of independent law firms. LegalFix, its corporate entity, and its officers, directors, employees, agents, and contractors do not provide legal advice, services, or representation—directly or indirectly.
The articles and information on the site are not legal advice and should not be relied upon—they are for information purposes only. You should become a LegalFix member to get legal services from one of our network law firms.
You should not disclose confidential or potentially incriminating information to LegalFix—you should only communicate such information to your network law firm.
The benefits and legal services described in the LegalFix legal plans are not always available in all states or with all plans. See the legal plan Benefit Overview and the more comprehensive legal plan contract during checkout for coverage details in your state.
Use of this website, the purchase of legal plans, and access to the LegalFix networks of law firms are subject to the LegalFix Terms of Service and Privacy Policy.